Richard Scalzo Biography and Net Worth

Rick Scalzo joined Crescent as chief financial officer in April 2025, bringing significant life science and public company finance experience. Previously, he spent more than five years at Dyne Therapeutics, most recently as senior vice president, head of finance and administration, overseeing several functions, including finance, accounting and facilities, leading the company’s transition to a public company and assisting in the execution of multiple financings. Prior to that, Mr. Scalzo served as corporate controller at Kaleido Biosciences, where he played a key role in the execution of the company’s initial public offering and led the accounting group’s transition from private to public company. Prior to joining Kaleido, he served as corporate controller at X4 Pharmaceuticals as well as Ocata Therapeutics. At Ocata, Mr. Scalzo was a significant contributor to the company’s acquisition by Astellas Pharma and the subsequent integration of the companies. He began his career in public accounting in the Health Industries practice at PricewaterhouseCoopers. Mr. Scalzo is a certified public accountant in the Commonwealth of Massachusetts, and received his BS in accounting from Boston College and his MBA from University of Massachusetts, Amherst.